Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
New mass spectrometry instrument and consumables launch during IMSC 2022
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Bringing next-gen cannabinoid therapeutics to cancer patients
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
